EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A VLP-based mRNA vaccine elicits potent humoral and cellular immunity against Oropouche virus

Yuren Shi iD, Guangxu Zhang, Siyu Lin, Mengyu Hu, Yuanzhou Wang, Haoyu Ge, Shuai Xia, Qian Wang iD, Shibo Jiang iD, Lu Lu iD

mBio · 11.02.2026 · 17 (2)

DOI: 10.1128/mbio.03653-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, erschienen am 11.02.2026. Verfasst von Yuren Shi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Medical Molecular Virology (Ministry of Education/National Health Commission/Chinese Academy of Medical Science), Shanghai Institut…. Hauptthemen laut MEDLINE: Orthobunyavirus, Vaccines, Virus-Like Particle, Immunity, Cellular, Immunity, Humoral. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Municipal Science and Technology Major Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oropouche virus (OROV) is reemerging in the Americas, along with a growing threat to global public health. Recent outbreaks have witnessed the first reported fatalities, vertical transmissions, and intercontinental importations of OROV, underscoring its expanding risk. Despite this, no vaccines or specific therapeutics are available, and fundamental research on OROV vaccinology and antigenicity remains limited. Here, we show that co-expression of the M polyprotein and nucleocapsid protein (NP) drives the assembly of OROV virus-like particles (VLPs) with high immunogenicity. Using the prototype strain OROV/sloth/Brazil/PA-UG-BeAn19991/1960, we developed an mRNA vaccine, M/N-vac, encoding these VLPs. Immunization with M/N-vac in mice elicited robust OROV-specific IgG and pseudovirus-neutralizing antibodies that cross-reacted with a contemporary circulating strain, hOROV/Brazil/AM-UKY-AM0088/2024. The vaccine also induced a durable, antigen-specific Th1-biased cellular immune response characterized by high-level interferon-gamma secretion. Additionally, we identified a highly conserved potential immunodominant epitope in BALB/c, N2-3, within the nucleocapsid protein. Furthermore, the VLP-encoding mRNA vaccine induced stronger OROV-specific humoral and cellular immune responses than the VLP protein vaccine. In vivo results based on immunization with M/N-vac demonstrate VLP-based vaccines to be a promising broad-spectrum strategy against OROV while providing novel insights into their antigenicity and design. IMPORTANCE Oropouche virus (OROV) is a reemerging pathogen with no approved countermeasures, and it poses a growing public health threat. In response, we have developed a virus-like particle-based mRNA vaccine that elicits potent and durable neutralizing antibodies against both historical and circulating OROV strains, alongside a robust Th1-biased cellular immune response. This study reports the design and development of a critically needed vaccine candidate and provides fundamental insights into OROV antigenicity, thus demonstrating the utility of the mRNA platform for rapid response to emerging viral threats.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OrthobunyavirusVaccines, Virus-Like ParticleImmunity, CellularImmunity, HumoralBunyaviridae InfectionsViral VaccinesAnimalsAntibodies, ViralMiceAntibodies, NeutralizingMice, Inbred BALB CNucleocapsid ProteinsFemaleImmunoglobulin GmRNA Vaccines

Stichwörter der Autor:innen

Oropouche virus (OROV)cross-reactive antibodiesmRNA vaccinevirus-like particles (VLPs)

Substanzen

Antibodies, ViralVaccines, Virus-Like ParticleAntibodies, NeutralizingNucleocapsid ProteinsViral VaccinesImmunoglobulin GmRNA Vaccines

Autor:innen und Institutionen

  • Key Laboratory of Medical Molecular Virology (Ministry of Education/National Health Commission/Chinese Academy of Medical Science), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Scien…
  • School of Basic Medicine, Dali University, Dali, China.

ORCID-Profile: Yuren Shi, Qian Wang, Shibo Jiang, Lu Lu

Förderung

  • Shanghai Municipal Science and Technology Major Project

Zitieren

APA

Shi, Y., Zhang, G., Lin, S., Hu, M., Wang, Y., Ge, H., Xia, S., Wang, Q., Jiang, S., & Lu, L. (2026). A VLP-based mRNA vaccine elicits potent humoral and cellular immunity against Oropouche virus. mBio, 17(2). https://doi.org/10.1128/mbio.03653-25

Vancouver

Shi Y, Zhang G, Lin S, Hu M, Wang Y, Ge H, et al. A VLP-based mRNA vaccine elicits potent humoral and cellular immunity against Oropouche virus. mBio. 2026;17(2). doi:10.1128/mbio.03653-25

BibTeX
@article{Shi2026,
  author = {Shi, Yuren and Zhang, Guangxu and Lin, Siyu and Hu, Mengyu and Wang, Yuanzhou and Ge, Haoyu and Xia, Shuai and Wang, Qian and Jiang, Shibo and Lu, Lu},
  title = {A VLP-based mRNA vaccine elicits potent humoral and cellular immunity against Oropouche virus},
  journal = {mBio},
  year = {2026},
  volume = {17},
  number = {2},
  doi = {10.1128/mbio.03653-25}
}
Kostenlos starten →